An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.
Publication
, Journal Article
Oehrlein, EM; US Food and Drug Administration Interviewees,
Published in: Value Health
June 2023
Duke Scholars
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
June 2023
Volume
26
Issue
6
Start / End Page
791 / 795
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Outcome Assessment, Health Care
- Humans
- Health Policy & Services
- Drug Development
- Drug Approval
- Data Collection
- 4407 Policy and administration
- 4203 Health services and systems
Citation
APA
Chicago
ICMJE
MLA
NLM
Oehrlein, E. M., & US Food and Drug Administration Interviewees, . (2023). An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Value Health, 26(6), 791–795. https://doi.org/10.1016/j.jval.2023.04.006
Oehrlein, Elisabeth M., and Elisabeth M. US Food and Drug Administration Interviewees. “An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.” Value Health 26, no. 6 (June 2023): 791–95. https://doi.org/10.1016/j.jval.2023.04.006.
Oehrlein EM, US Food and Drug Administration Interviewees. An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Value Health. 2023 Jun;26(6):791–5.
Oehrlein, Elisabeth M., and Elisabeth M. US Food and Drug Administration Interviewees. “An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.” Value Health, vol. 26, no. 6, June 2023, pp. 791–95. Pubmed, doi:10.1016/j.jval.2023.04.006.
Oehrlein EM, US Food and Drug Administration Interviewees. An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Value Health. 2023 Jun;26(6):791–795.
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
June 2023
Volume
26
Issue
6
Start / End Page
791 / 795
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Outcome Assessment, Health Care
- Humans
- Health Policy & Services
- Drug Development
- Drug Approval
- Data Collection
- 4407 Policy and administration
- 4203 Health services and systems